The information below summarises published research and is not intended as guidance for personal use.
Retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors, has drawn attention for its metabolic effects in early trials. A phase 2 study reported weight reductions of up to 24.2% over 48 weeks (PubMed). Yet the drug remains investigational, with no FDA-approved formulation available. This has not stopped compounding pharmacies from offering their own versions, a practice that raises questions about safety and legality.
Discovery and Early Research
Retatrutide emerged from efforts to build on the success of single and dual incretin agonists. Researchers hypothesized that adding glucagon receptor activation could enhance energy expenditure. Preclinical work in mice and non-human primates showed reductions in body weight and improvements in glucose tolerance. A 2021 patent filing by Eli Lilly described the molecule's structure and its binding affinities, which were later confirmed in early-phase human trials.
Early Research Era
Phase 1 data, published in 2022, indicated a safety profile comparable to other incretin-based therapies, with gastrointestinal side effects being most common (PubMed). Doses ranged from 1 mg to 12 mg weekly. The study enrolled 338 participants with type 2 diabetes or obesity. Mean weight loss at the highest dose reached 11.2 kg after 12 weeks, a signal that prompted accelerated development.
Modern Research Era
The phase 2 trial, which enrolled 338 adults with obesity or overweight, tested four retatrutide doses against placebo. At 48 weeks, the 12 mg group lost an average of 24.2% of baseline body weight, compared to 2.1% for placebo. Nearly all participants in the treatment arms achieved at least 5% weight loss. These results, presented at the American Diabetes Association's 83rd Scientific Sessions, fueled interest from both clinicians and the compounding sector.
Compounding and Regulatory Tensions
Compounding pharmacies have long operated under a legal framework that permits them to prepare customized medications when FDA-approved drugs are unavailable or unsuitable. The FDA's shortage list for semaglutide, a GLP-1 agonist, opened a pathway for compounded versions. However, retatrutide is not yet approved and is not on any shortage list, making its compounding legally ambiguous. An investigation by MedPage Today highlighted how some pharmacies are marketing compounded retatrutide directly to consumers, bypassing traditional prescribing safeguards (Retatrutide Compounding Under FDA Scrutiny After MedPage Today Investigation).
The FDA has not authorized compounded retatrutide, and the agency has issued warning letters to firms selling unapproved GLP-1 agonists. A recent FDA advisory panel meeting discussed broader oversight of compounded peptide therapies, though no vote specific to retatrutide has been scheduled. The panel's deliberations could influence how the agency enforces existing rules. In the meantime, some patients turn to compounding pharmacies when they cannot access brand-name GLP-1 drugs due to cost or shortages.
Pharmacy Access and Shortage Restrictions
The semaglutide shortage, which began in 2022, led to a surge in compounding of that drug. When the FDA removed semaglutide from its shortage list in 2023, many compounders shifted to other peptides, including retatrutide. This pivot has drawn scrutiny because retatrutide's safety profile is less established. Unlike semaglutide, which has years of post-marketing data, retatrutide's long-term risks are unknown. The FDA's tightening of semaglutide compounding rules may serve as a precedent for retatrutide, as explored in a recent analysis of regulatory actions (FDA Tightens Screws on Semaglutide Compounding: What It Means for Online Peptide Buyers).
Some compounding pharmacies argue that they fill a critical gap for patients who cannot tolerate approved formulations or who need alternative dosing. Yet the lack of standardized manufacturing and quality control raises concerns about potency and contamination. A 2023 analysis of compounded peptide products found that several samples contained impurities or incorrect dosages (PubMed). These findings underscore the risks of unregulated preparations.
Current Research Trajectory
Eli Lilly is conducting phase 3 trials of retatrutide for obesity, with results expected in 2025. The trials will assess cardiovascular outcomes and longer-term safety. Meanwhile, research on related peptides continues. Pinealon, a short peptide, has been studied for its neuroprotective effects in animal models, though human data are sparse. MOTS-c, a mitochondrial-derived peptide, showed metabolic benefits in small human studies, with one trial reporting improved insulin sensitivity after 4 weeks of treatment (n=20) (PubMed).
PT-141, a melanocortin receptor agonist, is approved for hypoactive sexual desire disorder but is sometimes compounded for off-label use. Ipamorelin, a growth hormone secretagogue, remains investigational. These peptides, like retatrutide, exist in a regulatory gray zone when compounded. The FDA's approach to retatrutide may set a template for how it handles other emerging peptides.
What Comes Next
The FDA is expected to clarify its stance on compounded retatrutide in the coming months, possibly through guidance documents or enforcement actions. A key factor will be whether the agency considers the drug to be in shortage once approved. If approved and widely available, compounding would likely be restricted. However, if access remains limited due to high demand or pricing, compounders may continue to operate in a legal loophole. The situation mirrors the early days of semaglutide compounding, which saw a similar pattern of regulatory lag.
International developments could also influence U.S. policy. Canada's approval of generic semaglutide has created a precedent for compounding access, as discussed in a recent article on cross-border regulatory dynamics (Aspen's Generic Semaglutide in Canada: A Regulatory Precedent for Retatrutide Compounding Access). If other countries allow compounding of retatrutide under certain conditions, it may pressure the FDA to adopt a more flexible approach.
For now, patients and providers must navigate a landscape where the desire for innovative therapies collides with the need for rigorous oversight. The coming FDA panel vote, if it occurs, will be a critical moment for defining the boundaries of pharmacy compounding in the age of peptide therapeutics.
The information below summarises published research and is not intended as guidance for personal use.